Plantar verrucae (or warts) Infections and Infestations
Conditions
Interventions
Participants with verrucae will be randomised in a 1:1 ratio to:
1. Removal of callus over the plantar verruca and needling under local anaesthesia
2. Removal of callus over the plantar verruca withou
Sponsors
University of Salford
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The participant has a verruca that, in the opinion of the health care professional, is suitable for both treatments: scalpel debridement and dry needling 2. They are aged 18 years and over
Exclusion criteria
Exclusion criteria: 1. The participant, in the opinion of the health care professional, is not suitable for local anaesthesia 2. They are currently in a trial evaluating other treatments for their verruca 3. They have impaired healing e.g., due to diabetes, peripheral vascular disease or any other condition 4. They are immunosuppressed or are currently taking immunosuppressant drugs such as oral corticosteroids 5. They are unable or unwilling to give informed consent 6. They are currently on renal dialysis 7. They have peripheral neuropathy 8. The participant is pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The participant’s verruca will be called the index verruca. In the case of a patient having multiple verrucae, the most painful or the largest verruca will be selected as the index verruca. The primary outcome will be complete clearance of the index verruca at 12 weeks after randomisation as determined by blinded assessment by a HCPC registered podiatrist working at the clinical site. ‘Clearance’ of verruca will be defined as the restoration of normal skin upon close inspection, with the return of normal dermatoglyphics to the treated area of skin, i.e., uninterrupted skin striae as assessed by the podiatrist. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Clearance of the index verruca at 24 weeks as assessed in the same way as the primary outcome 2. Complete clearance of all verrucae at 12 and 24 weeks as assessed in the same way as the primary outcome 3. Self-reported clearance of all verrucae at 12 and 24 weeks 4. Self-reported time to clearance of all verrucae 5. Recurrence of verrucae at 24 weeks 6. Number of verrucae remaining at 12 and 24 weeks 7. Change in size of the ‘index’ verruca at 12 and 24 weeks (digital photographs of the verrucae will be taken for analysis using an appropriate software package to measure the surface area of the verruca(e)) 8. Level of pain at 12 and 24 weeks 9. Level of pain 24 hours after the treatment 10. Number of treatments 11. Satisfaction with treatment at 12 and 24 weeks | — |
Countries
United Kingdom
Outcome results
None listed